

F. GANI¹, M. COTTINI², M. LANDI^{3,4}, A. BERTI^{5,6,7}, P. COMBERIATI^{8,9}, D. PERONI⁸,
G. SENNA^{10,11}, C. LOMBARDI¹²

Allergic rhinitis and COVID-19: friends or foes?

¹Allergy Outpatient Clinic, Turin, Italy

²Allergy and Pneumology Outpatient Clinic, Bergamo, Italy

³Pediatric National Healthcare System, Turin, Italy

⁴Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy

⁵Ospedale Santa Chiara, Trento, Italy

⁶Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy

⁷Thoracic Disease Research Unit, Mayo Clinic, Rochester (MN), U.S.A.

⁸Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy

⁹Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

¹⁰Department of Medicine, University of Verona, Verona University Hospital, Verona, Italy

¹¹Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy

¹²Departmental Unit of Allergology, Immunology and Pulmonary Diseases, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy

KEY WORDS

Allergic rhinitis; Coronavirus 2019; COVID-19; pandemic; SARS-Cov-2; allergy.

Corresponding author

Carlo Lombardi

Departmental Unit of Pneumology and Allergology

Fondazione Poliambulanza Istituto Ospedaliero

via Bissolati 57

25100 Brescia, Italy

ORCID ID: N/A

E-mail: carlo.lombardi@poliambulanza.it

Doi

10.23822/EurAnnACI.1764-1489.234

IMPACT STATEMENT

Allergic rhinitis symptoms can be distinguished from those of COVID-19, and patients with allergic rhinitis do not carry a higher risk of worst COVID-19 outcome.

Summary

Allergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide. In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.

In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.

AR patients seem to be protected from COVID 19 infection. Even if data about the influence of AR on the severity of COVID-19 disease are still not conclusive, it seems that being an AR patient does not increase the risk of poor COVID-19 prognoses. The clinical manifestation of AR can be distinguished by COVID-19 symptoms. Treating AR adequately is also strongly recommended, especially during pandemic.

Introduction

The COVID-19 pandemic caused by SARS-Cov-2 infection raised important questions as to whether some chronic comorbidities could favour the infectiveness or the prognosis of the disease. Concerning respiratory diseases, many studies were conducted analysing the effect of asthma and chronic obstructive pulmonary disease (COPD) on the risk of COVID-19 but data on allergic rhinitis (AR) are scarce, even if AR is a common disease affecting up to 40% of the general population (1). In this review, we evaluate whether AR patients are at higher risk for SARS-Cov-2 infection or COVID-19 outcomes and whether COVID-19 can influence AR symptoms and the psychological status of AR patients, both in the adult and in the paediatric population.

Methods

This work was not intended to be a systematic literature review but a comprehensive narrative review. The literature search has been conducted consulting the most relevant scientific databases: PubMed/MEDLINE, Scopus, Web of Science. Controlled vocabulary supplemented with keywords was used to search for all type of articles on allergic rhinitis and COVID-19. The search strategy included different terms, *i.e.*, allergic rhinitis, rhinitis, allergy, atopy, COVID-19 and SARS-CoV-2, and was restricted to English language articles.

Allergic Rhinitis and risk of non-SARS-CoV-2 viral infections

A high proportion of patients with AR and other atopic diseases have a predisposition to produce lower levels of type I interferon (INF) upon viral respiratory infections (2, 3). Through different mechanisms, Type 2 inflammation may have an inhibitory effect on the induction of type I interferon (4). Intriguingly, defective production of IFNs by plasmacytoid dendritic cells (pDCs) and epithelial cells have been described in severe atopic patients (5) with a consequent delayed and inefficient antiviral defense. In this context, a cross-regulation mechanism between FcεRI and TLRs in certain cell types such as pDCs has been described, which may explain why the crosslinking of IgE bound to FcεRI by allergens may result in a reduced TLR expression and ultimately in a decreased capacity to secrete type I interferons for viral defense (4, 6). Furthermore, IL-5-induced airway eosinophilia appears to be a negative regulator of TLR7 expression and antiviral responses (7). Such impairment of antiviral responses suggests that patients with asthma might be at high risk of COVID-19 morbidity and mortality.

Allergic Rhinitis and risk of SARS-CoV-2 infection


The prevalence of AR in the world is ranging from 10 to 40% varying according to different geographic areas (1). The spread of COVID-19 worldwide could have posed a significant psy-

chological burden to patients suffering from AR, because some nasal and ocular manifestations of AR are also possible presenting symptoms of COVID-19 illness (**figure 1**), therefore potentially leading to misinterpretation and anxiety. Nevertheless, available evidence shows that is not difficult to recognize and discriminate between these two different conditions. Bruno *et al.* (8) compared 40 patients suffering from AR with a similar group of 43 subjects affected by mild-moderate COVID-19 disease using the Sino-nasal Outcome Test 22 (SNOT 22). The mean overall score was higher in patients with COVID-19 compared to AR ones (39.9 *vs* 27.2). There was a significant difference in sneezing and blow nose between AR and COVID-19 patients ($p < 0.016$ and $p < 0.001$, respectively), while the COVID-19 group most frequently reported cough, loss of smell, fatigue during the day, reduced productivity and concentration, sadness and feeling of shame compared to AR group ($p < 0.001$). In a retrospective study, patients hospitalized with COVID-19 were interviewed via telephone by using the mini-Rhino-conjunctivitis Quality of Life Questionnaire (9). Among these patients, for those who were also affected by allergic rhino-conjunctivitis (10.8%), clinical manifestations of COVID-19 were regarded as completely different from AR in 62.8% of cases, and similar only in 18.2% of cases. No differences were found between sino-nasal symptoms in COVID-19 allergic *vs* non-allergic patients ($p = 0.288$), particularly for the prevalence of smell dysfunction. The authors concluded that patients with AR are very familiar with their symptoms, can distinguish AR from COVID-19 rhino conjunctival manifestations, and have the same upper airway COVID-19 manifestations of non-AR patients (9). Finally, the EUFOREA expert team statement evidenced that cough and fever were the most prominent symptoms of COVID-19, whereas conjunctivitis and itching were typical of AR (**figure 1**) (10).

A multicentre questionnaire study conducted on 301 nurses with AR characterized the impact of face masks on AR symptoms (11). They used both surgical and N95 masks. Nurses with intermittent AR symptoms showed a significant improvement in overall symptoms after wearing the mask, regardless of the type, but no change in specific ocular symptoms. The mechanism of protection could be a physical filtration of face masks and the potential physiological response to allergens by breathing humid and hot air (11).

The mandatory lockdown established by governmental authorities during the first wave of COVID-19 forced people to stay home for several months and this could have influenced the AR course in patients with house dust mite (HDM) allergy. Gelardi *et al.* (12) compared the results of SNOT-22 of years 2019 (pre-lockdown) and 2020 collected from 42 patients with AR to HDM (28% with asthma comorbidity). These authors showed that all SNOT-22 scores were higher in the lockdown period than the year before. However, only the scores relative to runny nose, need to blow nose, nasal obstruction were statistically

Figure 1 - Similarities and differences between allergic rhinitis and COVID-19 symptoms (adapted from (10)).



different from 2019 to 2020 ($p < 0.05$). Other non-specific parameters, such as difficulty falling asleep, waking up at night, be frustrated/restless/irritable, and sad were statistically significant ($p < 0.05$). Of note, there was a significant increase in the use of systemic antihistamine, and nasal decongestants ($p < 0.05$) to reduce nasal congestion but not in accordance with ARIA guidelines recommendations.

These findings may suggest that being quarantined at home for a long time may increase the exposure to HDM and focus on the importance of treating patients according to ARIA guidelines to control AR symptoms (13). Avoiding contact with allergens (indoor or outdoor) is the primary preventive measure in patients with respiratory allergies and a strategy with pharmacotherapy associated with allergen immunotherapy (AIT), when indicated, must be considered (12). Regarding pharmacologic therapy of AR, it is recommended to start early and use it regularly throughout the pollen season. None of the recommended therapy for seasonal AR is contraindicated in COVID-19 patients. In particular, it is not advised to suspend intranasal steroids as this therapy does not reduce immunity, is effective in normalizing the structure and function of the nasal mucosa, and reduces sneezing, one of the means for spreading the coronavirus (14). There are also preliminary data indicating that some corticosteroids as mometasone may suppress coronavirus replication (15). Systemic steroids, however, should be avoided, if possible, as they may suppress the immune system (14).

AIT should be continued in non-infected individuals and in those who completely recovered from COVID-19, whereas it should be interrupted in patients diagnosed with COVID-19 or suspected of having SARS-Cov-2 infection (16). Subcutaneous immunotherapy can be continued under strict safety protocols consider-

ing injection intervals expansion. AIT start in eligible patients is preferred to be in the sublingual route of administration to minimize in-person encounters for subcutaneous injections. Sublingual immunotherapy offers the possibility of taking it at home, thus avoiding the need to travel to or stay in an allergy clinic or doctor's office, which would increase the risk of infection (16).

Individuals with AR commonly report a higher proportion of anxiety, depression, and psychological disturbance than healthy people. In a cross-sectional study, 222 adults with AR and 133 healthy controls were asked to complete the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) questionnaires. The SAS and SDS scores were significantly higher in AR patients than control, with a prevalence of anxiety and depression of 25% and 19%, respectively, in the AR group (17). Interestingly, the same data obtained one week after the period of lockdown were lower than before the COVID-19 pandemic and correlate with AR symptoms. The authors conclude that the COVID-19 pandemic had no significant influence on the psychological status of patients suffering from AR and confirmed that symptom severity is an important factor affecting the anxiety and depression of AR patients (17).

On the contrary, a cross-sectional survey-based study, designed to assess the degree of depression and the risk of post-traumatic stress disorder using the patient's health questionnaires and the impact of Event Scale-Revised, evidenced that, during the period of quarantine due to COVID-19, the psychological impact in patients with allergic diseases ($n = 1,650$) was greater than in non-allergic controls ($n = 2,450$). There was no difference between allergic respiratory and non-respiratory groups but in the hyperarousal scale, respiratory patients had higher scores (mean 1.15 vs 0.99 $p = 0.013$). Unfortunately, the authors didn't distinguish between patients with allergic asthma from patients with AR (18). Even if at the beginning of the COVID-19 pandemic asthma and allergy were considered as possible risk factors for COVID-19, subsequent statements from international societies and expert scientific bodies concluded that allergic respiratory diseases do not constitute risk factors for severe COVID-19 (10, 14). Accordingly, in a study from China, Shi *et al.* found that the rate of combined allergy was low in COVID-19 patients. The ratio of combined asthma and AR were far lower than those of domestic morbidity, which might suggest that asthma and AR may not be a susceptibility factor for SARS-CoV-2 (19).

Can Allergic Rhinitis influence the outcomes of COVID-19?

COVID-19 pandemic has caused many hospitalizations and intensive care unit admission with a high burden on health care resources. For this reason, many studies were conducted to identify risk factors for severe COVID-19 outcomes. Elderly age, cardiovascular diseases, obesity, and diabetes have been associated with more severe disease (20). Available evidences about asth-

ma are not conclusive and it seems that only non-atopic asthma might be a risk factor for the severity of COVID-19 (21). Currently, there are only a few data about the risk of COVID-19 in patients with AR, and these are mostly indirect evidence from studies analysing the effect of atopy or asthma on COVID-19. In a retrospective study on 531 patients with SARS-Cov-2 induced pneumonia, Scala *et al.* (22) found that atopic subjects ($n = 57$; 10.7%) had a significantly lower prevalence of severe COVID-19 pneumonia than non-atopic patients (33.3% *vs* 67.7%; $p < 0.0001$). These authors concluded that atopic status may confer protection against COVID-19 infection, although but they didn't address what type of allergic disease participants suffered from (22). A recent American cohort study involving 1,043 COVID-19 patients was designed to understand the association between atopic conditions and COVID-19 severity. 257 (24.6%) had atopy and this condition was associated with a significantly lower odds of hospitalization for COVID-19 ($p < 0.004$) and length of hospitalization ($p < 0.008$). Patients suffering from AR ($n = 171$; 16.4%) had a lower rate of hospitalization ($p < 0.02$), length of hospitalization ($p < 0.001$), and lower duration of intubation ($p < 0.039$). Also, eczema was associated with a significantly reduced risk of hospitalization (23). Chhiba *et al.* (24) conducted a study to investigate if asthma could be a risk factor for the severity of COVID-19. Among 1,526 patients with COVID-19, 220 (14.4%) had asthma. The prevalence of AR was 35.9% in the asthmatics and 7.7% in the non-asthmatic groups ($p < 0.0001$), whereas rhinosinusitis was comorbidity in 35.9% of asthmatic patients *vs* 9.6% in non-asthmatic ones ($p < 0.0001$). Asthma was not associated with an increased risk of hospitalization, particularly in patients with AR and rhinosinusitis. The authors outlined the potential protective effect of Type-2 inflammation and perhaps of using inhaled corticosteroids, although the latter conclusion needs further investigation (24). Another study retrospectively analysed the comorbidity of 1172 hospitalized COVID-19 patients in Wuhan. 115 (9.8%) reported AR and tended to have higher asthma comorbidities. There was no difference in the frequencies of severe cases, need of mechanical ventilation or other treatment or complications (including severe acute respiratory syndrome) between patients with and without AR. The authors conclude that there is not any association between AR comorbidity and COVID-19 severity (25). On the contrary, Yang *et al.* (26) conducted a nationwide cohort study in South Korea involving 291,959 adult patients who were tested for SARS-Cov2 to determine the association of allergic disorders with the likelihood of a positive SARS-Cov-2 tests result and with clinical outcomes of the disease. The number of patients with positivity to SARS-Cov-2 was 7,340. The SARS-Cov-2 test positivity rate was 3.3% in individuals with AR compared to 2.8% in those without AR. Severe clinical outcomes from COVID-19 were observed in 4.7% and 3.7% of patients with and without AR, respectively. Also, patients with asthma had a significantly higher risk of severe COVID-19, but this data was particularly evident for non-allergic asthma,

whereas atopic dermatitis didn't show an association with severe clinical outcomes. They concluded that patients with respiratory allergic diseases are at higher risk of worse clinical outcome and that AR is associated with an increased likelihood of SARS-Cov-2 test positivity and worse clinical outcomes as death, intensive care admission, non-invasive ventilation, and longer hospital stay. The local immunologic environment in the respiratory system (impaired secretion of innate IFN) seems to be more important for SARS-Cov-2 infection than the systemic immunologic effects characteristic of atopic dermatitis (26). In a single-centre retrospective study with a small sample size (110 COVID-19 patients) in China, Shi *et al.* (19) observed a lower rate of comorbid allergy in patients with COVID-19 in comparison with the prevalence of allergic diseases in the general population. When excluding patients with other underlying diseases and stratifying COVID-19 patients into those with ($n = 21$) and without allergy history ($n = 44$), they found that patients with allergy demonstrated lower proportions of bilateral lung lesions on chest computed tomography scanning and severe illness and higher circulating total T-cell counts than those without allergy. Another study conducted in 949 COVID-19 patients showed that smell loss was associated with less severe COVID-19 and that a history of smell dysfunction ($p < 0.001$), AR ($p < 0.02$), rhinosinusitis ($p < 0.02$) was associated with a greater risk of acute smell loss in patients with COVID-19. So indirectly AR and rhinosinusitis could be related to a better course of COVID-19 disease (27). The host immune response is integral to determining susceptibility to SARS-CoV-2 infection and the severity of consequent COVID-19 (28). Recently, Larsson *et al.* (29) provide evidence to support that the genetic factors underlying predisposition to allergic disease are protective against COVID-19. They considered 136 uncorrelated ($r^2 < 0.02$) single nucleotide polymorphisms associated with a broad allergic disease phenotype (presence of at least one allergic disease, including AR, atopic dermatitis and asthma) at $p < 3 \times 10^{-8}$ in a meta-analysis of 13 genome-wide association studies with a total of 180129 cases and 180709 controls (without the three allergic diseases), all of European descent. Genetic predisposition to any allergic disease was associated with reduced susceptibility to COVID-19 but not clearly with the risk of being hospitalized with COVID-19. Secondary analyses based on genetic variants associated with different allergic diseases did not reveal associations with any particular allergic disease specifically, although the magnitude of the inverse association was most pronounced for AR albeit with broad confidence intervals (29).

Can Allergic Rhinitis be protective against poor outcomes of COVID-19?

As previously stated, some studies have suggested possible non-harmful or protective effects of AR on the clinical outcomes of COVID-19. Allergy is an immune response to allergen stimulation that is charac-

terized by elevated Type-2 cytokines and eosinophilic inflammation. The above findings raise the possibility that allergy might be a protective factor for COVID-19. AR might protect against poor outcomes in COVID-19 due to several possible mechanisms, including altered viral entry receptor expression, chronic type-2 inflammation, younger age and/or absence of comorbidities, increased adherence to therapy and intranasal corticosteroids use (30).

ACE2 receptor

The lack of susceptibility to COVID-19 in patients with pre-existing allergic asthma seems to be in contrast with the established link between these chronic respiratory conditions and susceptibility to common respiratory viruses, particularly rhinoviruses (31). However, rhinovirus uses the intercellular adhesion molecule 1 (ICAM-1) molecule as an entrance into respiratory epithelial cells, which is overexpressed in allergic airways as a marker of allergic inflammation (32). In contrast, COVID-19 uses another host cell receptor abundantly present in the oral mucosa and within the (healthy) airways, (*i.e.*, the angiotensin-converting enzyme-2 (ACE2) (33)), which plays a crucial role in the disease development and associated lung injury (34). Cofactors facilitating SARS-CoV-2 infectivity are transmembrane peptidase serine 2 (TMPRSS2), which cleaves the SARS-CoV-2 spike protein, and possibly protease furin (35). A lower expression of ACE2 has been described in airway cells of patients with AR and/or asthma. Jackson *et al.* found that nasal cat allergen led to a significant reduction in ACE2 mRNA expression in nasal brush samples in adult AR patients allergic to cats (36). Furthermore, Kimura *et al.* reported that IL-13 exposure reduced ACE2 expression in airway epithelial cells from patients with asthma and atopy (37). These findings suggest that patients with AR and allergic asthma might be protected from COVID-19 because of the low expression of ACE2 in their epithelial cells (38).

Inflammatory endotypes and COVID-19

Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, *etc.*), could therefore provide potential protective effects against COVID-19. In a retrospective study on patients with SARS-CoV-2-induced pneumonia, hospitalized in several Italian hospitals, atopic subjects showed a much lower occurrence of severe or very severe COVID-19 pneumonia (33.3% *vs* 67.7%, $p < 0.0001$) (22).

Eosinophilic inflammation

Further, the role of eosinophils, foes in asthma but possibly friends in COVID-19 infected lungs, needs to be established (39). Previous experimental studies indicated a potential role of eosinophils in promoting viral clearance and antiviral host defense (40). The capacity of eosinophils to protect against viral infection might therefore account for a low prevalence of asthmatic individuals among patients with COVID-19. Eosinophils are reduced in pe-

ripheral blood of SARS-CoV-2-infected patients, (41) therefore, it is tempting to speculate that increased numbers of eosinophils in the airways of asthmatic patients might be protective against the exaggerated inflammatory responses of the severe COVID-19 phenotype (39). The severity of AR is typically classified into a mild and a moderate-severe form based on symptom severity according to the ARIA guidelines (13). The clinical severity of AR correlates with the levels of eosinophils in the blood and nose. Recently, Chen *et al.* found that the eosinophil levels in the blood were significantly higher in mild and moderate-severe AR compared to healthy controls (42). Severe COVID-19 occurring in susceptible individuals may be associated with cytokine-mediated hyper-inflammation and associated coagulopathy with multisystem involvement and death (43). Markers of worsening disease include hypoxemia, lymphopenia, thrombocytopenia, and raised levels of IL-6, C reactive protein, ferritin, lactate dehydrogenase, and D-dimers. Eosinopenia may also be part of the overall cytopenic process in the early phase of severe COVID-19, with the later resolution of eosinophil counts being associated with clinical recovery (44). Peripheral blood eosinophil counts may, therefore, be an effective and efficient indicator in the diagnosis, evaluation, monitoring, and prognosis of COVID-19 patients (45).

Younger age and/or absence of comorbidities

Susceptibility and severity of COVID-19 infection increase with age (46); therefore, age is an important confounder in the assessment of the risk of contracting severe COVID-19. Expression of ACE2, the co-receptor for SARS-CoV-2, varies with age (47). Because Type-2 asthma sufferers tend to be younger than those with other comorbidities, the age factor probably explains why patients with asthma may not be at greater risk. However, to better address this question, age-adjusted models need to be formulated.

Paediatric Allergic Rhinitis and COVID-19

Beken *et al.* conducted a study in 107 pediatric patients after hospitalization for COVID-19 (48). Questionnaires investigating environmental factors and an allergic evaluation, including allergy testing and spirometry, were conducted. The authors concluded that asthma and AR were not risk factors for hospitalization in children due to COVID-19. The presence of a pet in the environment might have a protective effect. Dul and colleagues (49) evaluated the data extracted from electronic medical records of 182 children hospitalized for COVID-19 and showed that allergic diseases do not increase the susceptibility to SARS-CoV-2 infection and hardly influenced the course of COVID-19 in children. Finally, Jackson *et al.* (36) reported that high levels of allergic sensitization are associated with a reduction in the expression of the ACE-2 receptor which is the gateway to the virus. Regarding inhaled corticosteroid therapy, Bousquet *et al.* (14) report that out of 40 children with AR admitted to the Wuhan chil-

dren's hospital for Covid 19, about one third regularly used intranasal steroids as before, the other two-thirds did not: in these two groups of patients there was no difference in severity and prognosis COVID-19, and everyone has recovered well (unpublished data). Also, Cardinale *et al.* (50) stress the importance of continuing treatment with intranasal steroids and antihistamines both to control the symptoms and to avoid superinfections potentially dangerous for the lower respiratory tract. Furthermore, these authors also underline how the failure to control rhinitis with the classic symptoms, in particular sneezing, can favor the transmission of the virus. Some authors also suggested that montelukast could be also considered in pediatric age to treat AR during the COVID-19 pandemic, considering the potential anti-inflammatory action of this medication (51). Recommendations for AIT during the COVID-19 pandemic for adults with AR also apply to children (16, 50).

In the period of lockdown, allergic patients inevitably remained more confined to the home environment. Yucel *et al.* (52) raised the question of relapses in patients allergic to HDM. This study carried out during 75 days of lockdown on 81 children showed an improvement in lung function and consequently in asthma symptoms, probably due to the reduction of respiratory tract infections and exposure to outdoor pollution. On the contrary, the nasal symptoms were significantly worsened in subjects with allergic rhinitis, underlining the importance of environmental remediation measures indoors. In conclusion, it seems that COVID-19 affects childhood and adolescence, fortunately in a modest way (53, 54). However, for this very reason, allergic children must continue the therapies for their allergies and scheduled visits as must be the case for all chronic diseases.

Conclusions

AR patients seem to be protected from COVID 19 infection. Even if data about the influence of AR on the severity of COVID-19 disease are still not conclusive, it seems that being an AR patient does not increase the risk of poor COVID-19 prognoses. The clinical manifestation of AR can be distinguished by COVID-19 symptoms. Treating AR adequately is also strongly recommended in the COVID-19 pandemic era.

Conflict of interests

The authors declare that they have no conflict of interests.

References

1. Wise SK, Lin SY, Toskala E, *et al.* International consensus statement on allergy and rhinology: allergic rhinitis. *Int Forum Allergy Rhinol* 2018;8(2):108-352.
2. Durrani SR, Montville DJ, Pratt AS, *et al.* Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. *J Allergy Clin Immunol* 2012;130:489-95.
3. Wark PA, Johnston SL, Bucchieri F, *et al.* Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med* 2005;201:937-47.
4. Novak N, Cabanillas B. Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2. *Immunology* 2020;161(2):83-93.
5. Lebre MC, van Capel TM, Bos JD, Knol EF, Kapsenberg ML, de Jong EC. Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. *J Allergy Clin Immunol* 2008;122(5):969-976.
6. Gill MA, Bajwa G, George TA, *et al.* Counter-regulation between the Fc epsilon RI pathway and antiviral responses in human plasmacytoid dendritic cells. *J Immunol* 2010;184:5999-6006.
7. Hatchwell L, Collison A, Girkin J, *et al.* Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia. *Thorax* 2015;70(9):854-61.
8. Bruno C, Locatello LG, Cilona M, *et al.* Seasonal allergic symptoms in relation to COVID-19. *Allergy Rhinol (Providence)* 2020;11:2152656720968804.
9. Ferreli F, Gaino F, Russo E, *et al.* Clinical manifestation at the onset of COVID-19 and allergic rhinoconjunctivitis. *JACI Practice* 2020;8(10):3587-89.
10. Scadding GK, Hellings PW, Bachert, *et al.* Allergic respiratory disease care in the COVID_19 era: a EUFOREA statement. *World Allergy Organ J* 2020;13(5):100124.
11. Dror AA, Eisenbach N, Narshak T, *et al.* Reduction of allergic rhinitis symptoms with face mask usage during the COVID-19 pandemic. *J Allergy Clin Immunol Pract* 2020;8(10):3590-3.
12. Gelardi M, Trecca E, Fortunato F, *et al.* COVID-19: When dust mites and lockdown create the perfect storm. *Laryngoscope Investig Otolaryngol* 2020;5(5):788-90.
13. Bousquet J, Schünemann HJ, Togias A, *et al.* Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. *J Allergy Clin Immunol* 2020;145(1):70-80.e3.
14. Bousquet J, Akdis C, Jutel M, *et al.* Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. *Allergy* 2020;75(10):2440-4.
15. Lipworth B, Chan R, RuiWen Kuo C. COVID-19: Start with the nose. *J Allergy Clin Immunol* 2020;146(5):1214.
16. Klimek L, Akdis C, Bousquet J, *et al.* Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement. *Allergy* 2020;75(7):1546-54.
17. Wang Y, Shi C, Yang Y, *et al.* Anxiety and depression in allergic rhinitis patients during COVID-19 pandemic in Whuan, China. *Asian Pac J Allergy Immunol* 2021.
18. Gonzalez-Diaz SN, Martin B, Villarreal-Gonzalez RV, *et al.* Psychological impact of the COVID-19 pandemic on patients with allergic diseases. *World Allergy Organ J* 2021;14(3):100510.
19. Shi W, Gao Z, Ding Y, *et al.* Clinical characteristics of COVID-19 patients combined with allergy. *Allergy* 2020;75(9):2405-8.
20. Ejaz H, Alsrhani A, Zafar A, *et al.* COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health* 2020;13(12):1833-9.
21. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. *J Allergy Clin Immunol* 2020;146(2):327-329.e4.
22. Scala E, Abeni D, Tedeschi A, *et al.* Atopic status protects from severe complications of COVID-19. *Allergy* 2021;76(3):899-902.
23. Keswani A, Dhana K, Rosenthal JA, Moore D, Mahdavinia M. Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. *Ann Allergy Asthma Immunol* 2020;125(4):479-81.

24. Chhibba KD, Patel GB, Vu T, *et al.* Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. *J Allergy Clin Immunol* 2020;146(2):307-314.e4.
25. Wang H, Song J, Yao Y, *et al.* Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis. *Allergy* 2021;76(3):906-10.
26. Yang JM, Koh HY, Moon SY, *et al.* Allergic disorders susceptibility to and severity of COVID-19: A nationwide cohort study. *J Allergy Clin Immunol* 2020;146(4):790-8.
27. Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. *Ann Allergy Asthma Immunol* 2020;125:481-83.
28. Hadjadj J, Yatim N, Barnabei L, *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 2020;369:718-24.
29. Larsson SC, Gill D. Genetic predisposition to allergic diseases is inversely associated with risk of COVID-19. *Allergy* 2021;76(6):1911-3.
30. Farne H, Singanayagam A. Why asthma might surprisingly protect against poor outcomes in COVID-19. *Eur Respir J* 2020;56(6):2003045.
31. Jackson D J, Makrinioti H, Rana, B M J *et al.* IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. *Am J Respir Crit Care Med* 2014;190(12):1373-82.
32. Basnet S, Palmenberg AC, Gern JE. Rhinoviruses and Their Receptors. *Chest* 2019;155(5):1018-25.
33. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 2020;181(2):281-292.e6.
34. Song J, Zeng M, Wang H, *et al.* Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. *Allergy* 2021;76(2):483-496.
35. Lukassen S, Chua RL, Trefzer T, *et al.* SARSCoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *EMBO J* 2020;39:e105114.
36. Jackson DJ, Busse W, Bacharier LB, *et al.* Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol* 2020;146(1):203-206.e3.
37. Kimura H, Francisco D, Conway M, *et al.* Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. *J Allergy Clin Immunol* 2020;146(1):80-88.e8.
38. Matsumoto K, Saito H. Does asthma affect morbidity or severity of COVID-19? *J Allergy Clin Immunol* 2020;146(1):55-57.
39. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? *Allergy* 2021;76(3):866-8.
40. Rosenberg HF, Dyer KD, Domachowske JB. Respiratory viruses and eosinophils: exploring the connections. *Antivir Res* 2009;83(1):1-9.
41. Munblit D, Nekliudov NA, Bugaeva P, *et al.* StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. *Clin Infect Dis* 2021;73(1):1-11.
42. Chen Y, Yang M, Deng J, Wang K, Shi J, Sun Y. Elevated Levels of Activated and Pathogenic Eosinophils Characterize Moderate-Severe House Dust Mite Allergic Rhinitis. *J Immunol Res* 2020;2020:8085615.
43. Lipworth B, Chan R, Kuo CR. Predicting severe outcomes in COVID-19. *J Allergy Clin Immunol Pract* 2020;8:2582-4.
44. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. *J Allergy Clin Immunol* 2020;146:1-7.
45. Roca E, Ventura L, Zattra CM, Lombardi C. EOSINOPENIA: An early, effective, and relevant COVID-19 biomarker? *QJM* 2021;114(1):68-9.
46. Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-62.
47. Peters MC, Sajuthi S, Deford P, *et al.* COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. *Am J Respir Crit Care Med* 2020;202:83-90.
48. Beken B, Ozturk GK, Aygun FD, Aydogmus C, Akar HH. Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019. *Ann Allergy Asthma Immunol* 2021:S1081-1206(21)00053-3.
49. Du H, Dong X, Zhang JJ, *et al.* Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. *Allergy* 2021;76(2):510-32.
50. Cardinale F, Ciprandi G, Barberi S, *et al.* Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. *Ital J Pediatr* 2020;46(1):84
51. Kow CS, Hasan SS. Montelukast in children with allergic rhinitis amid COVID-19 pandemic. *Acta Paediatr* 2020;109(10):2151.
52. Yucel E, Suleyman A, Hizli Demirkale Z, Guler N, Tamay ZU, Ozdemir C. 'Stay at home': Is it good or not for house dust mite sensitized children with respiratory allergies? *Pediatr Allergy Immunol* 2021;32(5):963-70.
53. Licari A, Votto M, Brambilla I, *et al.* Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares. *Allergy* 2020;75(9):2402-5.
54. Riggioni C, Comberiati P, Giovannini M, *et al.* A compendium answering 150 questions on COVID-19 and SARS-CoV-2. *Allergy* 2020;75(10):2503-41.